Suchergebnisse - "Bustin, Frederique"

PubPharm (17)

1

A prospective, multicenter, noninterventional study of decision factors in the first-line treatment of metastatic non-small cell lung cancer

enthalten in: Acta oncologica (Stockholm, Sweden) | 2022

von Sibille, A. | Bustin, F. | Carestia, L. | +21

2

Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2021

von Peters, S. | Danson, S. | Ejedepang, D. | +19

3

Real life safety and effectiveness of nivolumab in older patients with non-small cell lung cancer : Results from the Belgian compassionate use program

enthalten in: Journal of geriatric oncology | 2020

von Joris, S. | Pieters, T. | Sibille, A. | +13

4

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

enthalten in: The New England journal of medicine | 2020

von Ramalingam, S. | Vansteenkiste, J. | Planchard, D. | +122

CommentIn: Lancet Oncol. 2020 Jan;21(1):e15. - PMID 31787537

5

Long term outcome after 48 Gy stereotactic ablative body radiotherapy for peripheral stage I non-small cell lung cancer

enthalten in: BMC cancer | 2019

von Dubaere, E. | Goffaux, M. | Wanet, M. | +18

6

Long term outcome after 48 Gy stereotactic ablative body radiotherapy for peripheral stage I non-small cell lung cancer

enthalten in: BMC cancer | 2019

von Dubaere, E. | Goffaux, M. | Wanet, M. | +18

7

Long term outcome after 48 Gy stereotactic ablative body radiotherapy for peripheral stage I non-small cell lung cancer

enthalten in: BMC cancer | 2019

von Dubaere, E. | Goffaux, M. | Wanet, M. | +18

8

A Multicenter Study to Assess EGFR Mutational Status in Plasma : Focus on an Optimized Workflow for Liquid Biopsy in a Clinical Setting

enthalten in: Cancers | 2018

von Sorber, L. | Zwaenepoel, K. | De Winne, K. | +19

9

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer

enthalten in: The New England journal of medicine | 2018

von Soria, J. | Ohe, Y. | Vansteenkiste, J. | +122

CommentIn: N Engl J Med. 2018 Jan 11;378(2):192-193. - PMID 29320658

10

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib : phase III randomized LUX-Lung 5 trial

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2016

von Schuler, M. | Yang, J. | Park, K. | +118

CommentIn: Ann Oncol. 2016 Mar;27(3):367-8. - PMID 26924595